H5N1 pre-pandemic influenza vaccine

The H5N1 pre-pandemic influenza vaccine is a monovalent inactivated or recombinant protein-based vaccine developed to provide active immunization against the highly pathogenic avian influenza A/H5N1 virus. It is designed for use before or at the onset of an anticipated pandemic caused by an emergent human-transmissible strain of H5N1. The primary mechanism involves stimulating adaptive immunity—specifically humoral and cellular responses—against the hemagglutinin (HA) glycoprotein of the H5 subtype, thereby priming the immune system to recognize and neutralize circulating or emerging strains within this clade[3][4][8]. Adjuvants such as AS03 or MF59 are often included to enhance immunogenicity and antigen-sparing properties[6]. These vaccines are intended for stockpiling and rapid deployment in case of a pandemic threat. Developers include major pharmaceutical companies with expertise in large-scale flu vaccine production.

Brand names

PrepandrixPandemic influenza vaccine H5N1 AstraZeneca

Other names

AS03-H5N1 vaccineAS-03-H5N1 vaccineAS 03-H5N1 vaccineSplit virion inactivated H5N1 vaccinePandemic influenza A (H5) monovalent virus vaccine